Drug withdrawals in the United States: A systematic review of the evidence and analysis of trends

Current Drug Safety

Volumn 2, Issue 3, 2007, Pages 177-185

  Issa, Amalia M ^a   Phillips, Kathryn A ^b   Van Bebber, Stephanie ^b   Nidamarthy, Hima G ^a   Lasser, Karen E ^c   Haas, Jennifer S ^d   Alldredge, Brian K ^b   Wachter, Robert M ^e   Bates, David W ^d  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CAMBRIDGE HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug safety; Drug surveillance; Evidence base; Pharmacoepidemiology; Policy implications; Prescription drug withdrawals

Indexed keywords

ASTEMIZOLE; BROMFENAC; CERIVASTATIN; CHLORMEZANONE; CISAPRIDE; DEXFENFLURAMINE; ETRETINATE; FENFLURAMINE; FLOSEQUINAN; GREPAFLOXACIN; HYDROMORPHONE; LEVACETYLMETHADOL; MIBEFRADIL; PEMOLINE; PEMOLINE MAGNESIUM; RAPACURONIUM BROMIDE; ROFECOXIB; TERFENADINE; THIORIDAZINE; TROGLITAZONE; VALDECOXIB;

CARDIOVASCULAR DISEASE; DRUG FATALITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEPATITIS; HUMAN; JAUNDICE; LIVER DYSFUNCTION; LIVER FAILURE; MEDICAL RESEARCH; PATIENT SAFETY; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PULMONARY HYPERTENSION; QT PROLONGATION; REFERENCE DATABASE; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; TERATOGENICITY; TORSADE DES POINTES; UNITED STATES; VALVULAR HEART DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG AND NARCOTIC CONTROL; EVIDENCE-BASED MEDICINE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 35348840852     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607781668855     Document Type: Review

References (74)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
3. Gandhi TK, Weingart SN, Borus J, et al. Patient safety: Adverse drug events in ambulatory care. N Engl J Med 2003; 348: 1556-64.
4. Smith CC, Bennett PM, Pearce RM, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996; 42: 423-9.
5. Wasserfallen J, Livio F, Buclin T. Tillet L, Yersin B, Biolaz J. Rate, type and cost of adverse drug reactions in emergency department admissions. Eur J Int Med 2001; 12: 442-7.
6. Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-67.
7. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: Cross sectional incidence study. BMJ 2000; 320: 1036.
8. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-66.
9. Wadman M. Drug safety special: The safety catch. Nature 2005; 434: 554-6.
10. Institute of Medicine. The future of drug safety: Promoting and protecting the health of the public. Available at: http://newton.nap.edu/ catalog/11750.html Accessed: December 1, 2006.
11. US Department of Health and Human Services and Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. Available at: www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html Accessed: on December 1, 2006.
12. Okie S. What ails the FDA? N Engl J Med 2005; 352: 1063-6.
13. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-20.
14. Food and Drug Administration. CDER 1999 Report to the Nation: Improving public health through human drugs. Rockville, MD, 2000.
15. Food and Drug Administration. CDER 2000 Report to the Nation: Improving public health through human drugs. Rockville, MD, 2001.
16. Food and Drug Administration. CDER 2001 Report to the Nation: Improving public health through human drugs. Rockville, MD, 2002.
17. Food and Drug Administration. CDER 2002 Report to the Nation: Improving public health through human drugs. Rockville, MD, 2003.
18. Food and Drug Administration. CDER 2003 Report to the Nation: Improving public health through human drugs. Rockville, MD, 2004.
19. Food and Drug Administration. CDER 2004 Report to the Nation: Improving public health through human drugs. Rockville MD, 2005.
20. Food and Drug Administration. CDER 2005 Report to the Nation: Improving public health through human drugs. Rockville, MD, 2006.
21. Food and Drug Administration. Med Watch product safety information. Available at: http://www.fda.gov/Medwatch/safety.htm
22. Thomson Micromedex. DRUGDEX system MICROMEDEX healthcare series [proprietary database on the Internet]. Greenwood village (CO), 2005
23. Physicians' desk reference 47th-60th edition, Montvale NJ: Medical Economics Co, 1993-2006.
24. Mosby's Drug Consult 2005.2 CD-ROM, 9th Edition, Elsevier. Available through The Methodist Hospital Health System, Houston, TX
25. Prescription Drug User Fee Act of 1992. Pub L No. 102-571, 106 Stat. 4491.
26. Berndt ER, Gottschalk AH, Philipson TJ, Strobeck MW. Industry funding of the FDA: Effects of PDUFA on Approval times and withdrawal rates. Nat Rev Drug Discov 2005; 4: 545-54.
27. Kaitin KI. The prescription drug user fee act of 1992 and the new drug development process. Am J Ther 1997; 4: 167-72.
28. Olson MK. Explaining reductions in FDA drug review times: PDUFA matters. Health Aff (Millwood) 2003; Jul-Dec Suppl Web Exclusives: W4-S1-W4-S2.
29. Olson MK. Managing delegation in the FDA: Reducing delay in new-drug review. J Health Polit Policy Law 2004; 29: 397-430.
30. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: Do recent market removals mean there is a problem? JAMA 1999; 281: 1728-34.
31. Tufts Center for the Study of Drug Development. Drug safety withdrawals in the U.S. Not linked to speed of FDA approval Tufts Center for the Study of Drug Development Impact Report 2005; 7: 1-4.
32. Mehta C, Patel N, eds. StatXact for Windows. Cambridge, MA: Cytel Software Corporation, 1999.
33. United States General Accounting Office. Food and Drug Administration: Effect of user fees on drug approval times, withdrawals, and other agency activities. GAO-02-958 2002; Available at: http://www.gao.gov/ new.items/d02958.pdf Accessed: November 30, 2006.
34. Wysowski DY, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005; 165: 1363-9.
35. Fung M, Thornton A, Mybeck K, Wu JHH, Horbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Info J 2001; 35: 293-317.
36. Bakke O, Manocchia M, De Abajo FJ, Kaitin K, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: A regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-117.
37. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infraction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005; 365: 475-81.
38. Graham DJ. Testimony of David J. Graham, MD, MPH November 18, 2004. Available at: http://finance.senate.gov/hearings/testimony/2004test/ 141804dgtest.pdf Accessed: December 1, 2006.
39. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs Accessed: December 1, 2006.
40. Slone Epidemiology Center. Patterns of medication use in the United-States 2005: A report from the Slone survey. Available at: http//www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2005.pdf Accessed: November 30, 2006.
41. Goldman SA. Communication of medical product risk: How effective is effective enough? Drug Saf 2004; 278: 519-534.
42. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006; 166: 338-44.
43. Maggon K. Best-selling human medicines 2002-2004. Drug Discov Today 2005; 10: 739-42.
44. Bates D. Drugs and adverse drug reactions: How worried should we be? JAMA 1998; 279: 1216-17.
45. Frantz S. Drug safety special: Chasing Shadows. Nature 2005; 434: 557-57.
46. Okie S. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 2005; 352: 1173-6.
47. Moore, SW. An overview of drug development in the United States and current challenges. South Med J 2003; 96: 1244-1255.
48. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22: 151-85.
49. Roden DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation 2005; 111: 256-48.
50. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. Qual Saf Health Care 2005; 14: 221-6.
51. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
52. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003; 348: 1556-64.
53. Bates D, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 1: 29-34.
54. Woosley RL. Discovering adverse feactions: Why does it take so long? Clin Pharmacol Ther 2004; 76: 287-9.
55. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
56. Ernst FR, Grizzle AJ. Drug-Related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc 2001; 41: 192-99.
57. Guyatt G, Cook D, Haynes B, Evidence based medicine has come a long way. BMJ 2004; 329: 990-1.
58. Bates DW, Evans RS, Murff H, Stetson PD, Pizziferii L, Hripcsak G. Policy and the future of adverse event detection using information technology. J Am Med Inform Assoc 2003; 10: 226-8.
59. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17-29.
60. Issa AM. Pharmacogenomic profiling in post-marketing surveillance: Prospects and challenges. Pharmacogenomics 2003; 4: 647-55.
61. Issa AM. The regulation of pharmacogenomics-based drugs and policy making. Curr Top Med Chem 2004; 4: 1455-60.
62. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001; 286: 2210-79.
63. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development priming the pipeline Nat Rev Drug Discov 2006; 5:463-9.
64. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22: 298-305.
65. Ingelman-Sundberg M, Rodriquez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1563-70.
66. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-74.
67. Priori SG, Napolitaino C, Schwartz PJ. Low penetrance in the long-QT syndrome: Clinical impact. Circulation 1999; 99: 529-33.
68. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: Potential tool for improving clinical drug development and prescribing. Drug Saf 2004; 27: 145-72.
69. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: The evolving role of Pharmacogenetics. Heart Rhythm 2005; 2: S30-S37.
70. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat Genet 2005; 37: 671-681.
71. Hollon MF. Direct-to-Consumer advertising: A haphazard approach to health promotion. JAMA 2005; 293: 2030-33.
72. Avorn J. FDA Standards-Good enough for Government work? N Engl J Med 2005; 10: 969-72.
73. Waxman HA. The lessons of Vioxx- Drug safety and sales. N Engl J Med 2005; 352: 2576-78.
74. Wachter RM, Shojania K. Internal Bleeding: The truth behind America's perrifying epidemic of medical mistakes. New York, Rugged Land. 2004.